Developing breakthrough AXL therapeutics to improve patients' lives

Developing breakthrough AXL therapeutics to improve patients' lives
Learn About Us
Background
DecorationDecoration

Information about the Warrants

Old woman

BerGenBio is a clinical-stage biopharmaceutical company developing innovative drugs for aggressive diseases including cancer and severe respiratory infections

Recent News

BerGenBio ASA – Final results for the first exercise period for warrants issued in connection with rights issue

BerGenBio ASA – Preliminary results for the first exercise period for warrants issued in connection with rights issue

BerGenBio ASA – Last day of the first exercise period for warrants issued in connection with rights issue

BerGenBio ASA – Information about the first exercise period for warrants issued in connection with rights issue

BerGenBio ASA Mandatory notification of trade by primary insiders and close associates

BerGenBio ASA - Commencement of the first exercise period for warrants issued in connection with rights issue

BerGenBio Reports Third Quarter 2023 Financial Results

BerGenBio ASA: Invitation to third quarter 2023 results webcast

BerGenBio Announces Data from Biomarker Analyses in 2L NSCLC